GlassScriptPhysician profile
Nicolas C Martin
NPI 1477668606
$1,863.47
in general payments reported to CMS, 2019-2025
11 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $17.16 · 2021: $14.74 · 2022: $239 · 2023: $751 · 2024: $197 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $775.65 | 2022-2025 | Puraply, Puraply Wound Matrix, Affinity |
| Wright Medical Technology, INC. | $339.76 | 2019 | |
| Smith+Nephew, INC. | $241.57 | 2023 | Grafix Pl, Grafix Xc, Stravix |
| Integra Lifesciences Corporation | $183.46 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Stryker Corporation | $181.03 | 2021-2025 | Citrefix, Viaflow |
| Elite Orthopedics, LLC | $31.01 | 2019-2023 | |
| Kerecis Limited | $30.83 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Ethicon US, LLC | $27.57 | 2022 | |
| Averitas Pharma INC. | $22.64 | 2024 | Qutenza |
| Ermi LLC | $17.16 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.79 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.